Algert Global
ATRA icon

Algert Global’s Atara Biotherapeutics ATRA Stock Holding History

Algert Global’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-542
Closed -$214K – 1176
2021
Q4 		$214K Sell
542
-180
-25% -$75.8K 0.03% 830
2021
Q3 		$323K Buy
722
+235
+48% +$84.2K 0.04% 734
2021
Q2 		$189K Buy
+487
New +$174K 0.06% 360
2020
Q1 		– Sell
-1,190
Closed -$490K – 413
2019
Q4 		$490K Buy
+1,190
New +$410K 0.15% 210

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Algert Global's ATRA Position: Q1 2022 in Review

Algert Global sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 542 shares — an estimated $214K sold.

Algert Global first reported a position in ATRA in Q4 2019 and held it in 4 quarters. The position peaked at $490K in Q4 2019. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Algert Global reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Algert Global sold 542 Atara Biotherapeutics shares in Q1 2022, an estimated $214K.
  • Algert Global first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 4 quarters.
  • Algert Global's Atara Biotherapeutics position peaked at $490K in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Algert Global's 13F filing for Q1 2022, filed 16 May 2022.